Peptides commonly discussed in recovery and performance programs

Learn about the peptides generating the most attention across recovery and performance, why healthcare organizations are watching them, and what current research says about each.

Peptide therapy vial highlighting recovery, performance, and metabolic health applications.
Credit: OpenLoop Health

Key takeaways

  • Interest is high. Searches for “peptide” rose roughly 398% year over year between June 2025 and July 2026, according to Google Ads Keyword Planner data.¹
  • No peptide in this article is FDA-approved for recovery or performance. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed.²
  • Federal policy changed on October 28, 2026. HHS issued an interim enforcement discretion policy covering six peptides, including BPC-157, MOTS-c, Semax, and KPV, under defined conditions and route-of-administration limits.³,⁴ This is not FDA approval, and it is not formal listing on the 503A Bulks List, which requires rulemaking. Sermorelin follows a different pathway, described below.
  • Human research is limited. Much of the published work on these peptides comes from laboratory and animal studies. FDA is expected to consider additional peptides before the end of February 2027, and state laws apply in addition to federal policy.⁵,⁶

As interest in recovery and performance services grows, organizations are weighing whether peptide offerings fit alongside their longevity, metabolic health, and wellness programs. The peptides they ask about vary widely in how much is known: some have a history of regulated medical use, while others have been studied mainly in cells or animals, with limited human data. 

This article covers peptides commonly discussed in these programs that fall within current federal compounding policy, following the FDA’s July 2026 advisory committee review and the HHS interim policy of October 28, 2026. We selected them for where they stand in that framework, not for effectiveness or popularity. For each, we explain what it is, what the research does and does not show, and its current regulatory status.

This article is general information, not medical or legal advice, and does not recommend any peptide or establish that one is safe or effective for a particular use. Compounding and prescribing must comply with applicable federal and state law and rest on an individualized clinical assessment.

What are peptides?

Peptides are short chains of amino acids. By convention, chains of roughly two to 50 amino acids are called peptides, and longer chains are called proteins. Many peptides occur naturally in the body, where they act as signaling molecules that help regulate processes such as hormone signaling, metabolism, immune function, and tissue repair.⁷

Some peptides are established medicines. Insulin and the GLP-1 receptor agonists are well-known examples, and more than 80 peptide drugs have been approved worldwide.⁷ Those medicines went through FDA review, with clinical trials supporting specific uses. The peptides in this article are different. None is FDA-approved for recovery or performance, and none shares the clinical trial record of those approved drugs.

What does research show about peptides for recovery and performance?

Researchers have explored peptides in relation to tissue repair, musculoskeletal health, metabolic health, and exercise physiology. Evidence varies widely by peptide. For most of those discussed here, the research comes mainly from cell and animal studies, and human data are limited, early-stage, or uncontrolled. Well-controlled human trials showing that these peptides improve recovery or athletic performance are lacking.⁵

Why are peptides drawing so much attention?

According to Google Ads Keyword Planner, searches for “peptide” increased roughly 398% year over year between June 2025 and July 2026, averaging more than 600,000 searches per month.¹ It’s important to note that search volume reflects curiosity, not understanding or evidence.

Federal policy is also moving quickly. FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides in July 2026, and HHS issued an interim policy in October.³,⁸ HHS has said the policy is meant in part to discourage the continued, widespread use of certain research-use-only peptides, and, in its Federal Register notice, to expand patient access given the lack of approved products.²,⁹

What does “compounded” mean, and why does it matter here?

Compounding is the preparation of a medication tailored to an individual patient by a licensed pharmacist or physician. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacy may prepare a drug for an identified patient based on a valid prescription.⁹ Compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness, or quality before they are marketed.²

How do compounded drugs qualify for 503A exemptions?

To qualify for the 503A exemptions, a compounded drug must be made from a bulk drug substance that meets one of three conditions: it complies with a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on FDA’s 503A Bulks List.³,¹⁰ 

The substance must also come from an FDA-registered manufacturer and be accompanied by a certificate of analysis.⁹ While FDA evaluates nominated substances, its interim policy sorts them into categories. For Category 1 substances, FDA has said it does not intend to take action against compounders when the policy’s conditions are met. Category 1 is an enforcement position. It is not approval.¹⁰

Each peptide below has a regulatory status that describes where the substance sits in the federal compounding framework. It does not describe whether the peptide has been shown to be safe or effective for any use.

How federal policy works today

Four terms are easy to confuse. Each means something different.

TermWhat it isWhat it is not
Advisory committee recommendationOn July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax.³A binding decision. The vote was advisory and non-binding, and FDA staff had proposed listing none of them, citing limited product characterization and human evidence.⁵
HHS interim enforcement discretionAs of October 28, 2026, HHS does not intend to act against state-licensed pharmacies, federal facilities, or licensed physicians that compound the six peptides when the policy’s ten conditions are met (which include route-of-administration limits, single-ingredient products, FDA-registered manufacturers, certificates of analysis, patient-specific prescriptions, and adverse event reporting).³,¹⁰FDA approval. It does not cover 503B outsourcing facilities or products sold as research chemicals or dietary supplements, and HHS may revisit it if a safety or quality issue arises. The Federal Register notice published October 30, 2026 opened a public comment period.²,¹⁰
Formal listing on the 503A Bulks ListA permanent addition that requires FDA notice-and-comment rulemaking.In effect yet. That rulemaking has not happened for these peptides.²,³
FDA approvalA separate process, based on clinical trials of a specific product for a specific use.In place here. None of the peptides in this article has FDA approval for any longevity or aesthetic purpose.

Even when a substance is within an enforcement policy, all other section 503A conditions and applicable state laws remain in force. A favorable advisory vote does not establish that a particular compounded drug may be lawfully prepared, prescribed, dispensed, or advertised.

A note for operators working with athletes

Anti-doping rules are separate from FDA rules. Several of the substances discussed here, including BPC-157, MOTS-c, and sermorelin, have been reported as prohibited under the World Anti-Doping Agency’s Prohibited List.¹²,¹³

Athletes subject to anti-doping testing should check with their governing body before using any of them.

Peptides and their current regulatory status

Each summary below states whether the research was done in cells, animals, or people, and gives the peptide’s current regulatory status. A summary of research is not a statement that a peptide is safe or effective.

Sermorelin

What is Sermorelin?

Sermorelin is a synthetic peptide made of the first 29 amino acids of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone. It is not growth hormone itself.¹⁴

What the research shows 

FDA approved sermorelin acetate products (brand name GEREF) for diagnostic testing of growth hormone secretion and for treating growth hormone deficiency in children. The manufacturer later discontinued them, and FDA determined that the discontinuation was not for reasons of safety or effectiveness.¹⁵ A published review describes sermorelin’s use as a diagnostic test and, based on limited data, in treating some children with idiopathic growth hormone deficiency.¹⁴ Sermorelin is not FDA-approved for recovery or performance, and compounded sermorelin is not FDA-approved for any use. That research does not establish benefits for these purposes.

Regulatory status 

Sermorelin acetate was the active ingredient in GEREF, an FDA-approved drug discontinued for commercial reasons, not safety or efficacy (per FDA). 503A pharmacies compound sermorelin under patient-specific prescriptions on that basis. Compounded sermorelin isn’t FDA-approved and must meet all federal and state compounding requirements.

BPC-157 acetate

The next four peptides are among the six covered by HHS’s interim policy.

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide.

What the research shows 

Most published research comes from laboratory and animal studies, including studies of gastrointestinal, tendon, ligament, and muscle injury models. A 2025 systematic review described the research as promising in animals and limited in humans.¹⁶

In July 2026, FDA reviewed BPC-157 for ulcerative colitis. FDA staff concluded that evidence was lacking to determine whether it is effective for that condition. FDA also reported adverse event case reports involving compounded BPC-157 products, although it noted that the information available did not show whether BPC-157 caused the events, and it raised immunogenicity concerns for certain routes of administration.¹⁷,¹⁸ These findings do not establish that BPC-157 is safe or effective for recovery or any other use.

Regulatory status

Within HHS’s interim enforcement discretion policy for subcutaneous, intramuscular, oral, and topical dosage forms, when the policy’s conditions are met.³,⁴ Not FDA-approved. Not on the 503A Bulks List.

TB-500 acetate

What is TB-500?

A synthetic peptide that corresponds to a short fragment (amino acids 17–23) of thymosin beta-4, a 43-amino-acid protein the body produces naturally.

What the research shows

Most of what is known about TB-500 and thymosin beta-4 comes from laboratory and animal studies; human data are limited and do not establish that it is safe or effective. In preclinical models, researchers have looked at possible roles in repairing heart tissue after a heart attack²⁵,²⁶,²⁷ and in healing injuries to the cornea²⁸,²⁹,³⁰ and the skin.³¹,³² 

The biopharmaceutical company RegeneRx carried thymosin beta-4 into Phase II human trials for conditions including dry eye disease, the genetic skin disorder epidermolysis bullosa, and diabetic (neuropathic) ulcers, with mixed results. No large Phase III trial has been completed for TB-500 itself, and the available evidence does not establish a recovery, performance, or other clinical benefit.

Regulatory status

Within HHS’s interim enforcement discretion policy for subcutaneous or intramuscular injectable dosage forms, when the policy’s conditions are met.⁴ Not FDA-approved. Not on the 503A Bulks List.

MOTS-c acetate

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It was first described in 2015.¹⁹

What the research shows

In that original study, MOTS-c treatment in mice was associated with effects on insulin sensitivity and with protection from diet-induced obesity. Published research to date consists largely of cell and animal studies and early human measurements of circulating MOTS-c levels.¹⁹ This work does not establish that MOTS-c is safe or effective for any use in people, including exercise performance. In its July 2026 briefing materials, FDA reported finding little or no human safety and effectiveness data for MOTS-c.⁵

Regulatory status

Within HHS’s interim enforcement discretion policy for subcutaneous or intramuscular injectable dosage forms, when the policy’s conditions are met.⁴ Not FDA-approved. Not on the 503A Bulks List.

Semax free base

What is Semax?

Semax is a synthetic seven-amino-acid peptide related to a fragment of adrenocorticotropic hormone (ACTH).²⁰ It was developed in Russia, where it is registered as a medicine for certain neurological indications. It is not FDA-approved.²¹

What the research shows

Published laboratory research, such as a rat study, has examined Semax’s effects on brain-derived neurotrophic factor (BDNF) signaling in the hippocampus.²⁰ That evidence is preclinical, and it does not address recovery or physical performance. Human data are concentrated in the Russian clinical literature, and Western clinical research is more limited. In July 2026, FDA staff proposed that Semax not be added to the 503A Bulks List, citing among other concerns gaps in product characterization and limited human evidence. The advisory committee voted to recommend it.³,²¹

Regulatory status

Within HHS’s interim enforcement discretion policy for intranasal use, when the policy’s conditions are met.⁴ Not FDA-approved. Not on the 503A Bulks List.

KPV acetate

What is KPV?

KPV is a three-amino-acid peptide (lysine-proline-valine) that corresponds to the end of alpha-melanocyte-stimulating hormone (alpha-MSH). Researchers have studied its anti-inflammatory effects, mainly in models of gut inflammation.²²

What the research shows

In one study, KPV reduced inflammatory signaling in human intestinal and immune cell lines and reduced inflammatory markers in two mouse models of colitis.²² Those are cell and animal findings. FDA’s July 2026 review evaluated KPV for wound healing and inflammatory conditions and reported finding no information on KPV administered to humans.¹⁸,²³ Interest in recovery settings rests on mechanistic and preclinical research and does not establish clinical benefit.

Regulatory status

Within HHS’s interim enforcement discretion policy for topical and oral dosage forms, when the policy’s conditions are met.⁴ Not FDA-approved. Not on the 503A Bulks List.

Peptides FDA has announced for 2027 advisory committee review

FDA has announced that its advisory committee will meet again before the end of February 2027 to consider five additional peptides for the 503A Bulks List: 

  • Cathelicidin (LL-37)
  • GHK-Cu
  • Dihexa acetate
  • Melanotan II
  • PEGylated mechano growth factor (PEG-MGF).⁶ 

As of this writing, FDA has not posted a final meeting date. Being scheduled for advisory committee consideration does not establish compounding eligibility, safety, effectiveness, or likely inclusion on the 503A Bulks List.

Non-injectable GHK-Cu is an exception on eligibility: it appears in Category 1 of FDA’s list of bulk drug substances nominated for 503A compounding and may be compounded under FDA’s interim policy when that policy’s conditions are met. 

Injectable GHK-Cu is not in Category 1.¹⁰,²⁴ The other four substances are not covered by HHS’s interim policy and should not be assumed to be available for 503A compounding.⁴

For a broader look at peptides discussed in longevity and aesthetics programs, see our companion article.

5 things healthcare organizations should keep in mind when building a peptide program

The peptide landscape is changing quickly. Organizations considering peptide programs should keep these points in mind:

  1. Policy can change. HHS may revisit or amend the interim policy, and final rulemaking could change its conditions.²,³
  2. Sourcing matters. The policy’s conditions reach the supply chain, including FDA-registered manufacturers and certificates of analysis.³ Research-use-only products are outside the policy.¹¹
  3. State law applies. State pharmacy and medical practice laws apply in addition to federal policy. Not all peptides are available in all states or through all pharmacies.
  4. Claims should match the evidence. Marketing and patient-facing materials should not describe compounded peptides as FDA-approved, cleared, endorsed, or proven, and should not imply guaranteed results or improved athletic performance. They should describe the evidence accurately, including where it comes from animal or early human studies.
  5. Documentation matters. Clinical documentation and informed consent should reflect each product’s compounded, non-FDA-approved status.

Organizations should consult qualified legal counsel about their specific obligations.

Build a peptide therapy program with OpenLoop®

Whether additional peptides move through FDA review or remain under evaluation, healthcare organizations face the same challenge: preparing for patient interest while building programs designed to adapt as federal and state requirements change.

A program needs clinical protocols, clinician networks, pharmacy partnerships, patient workflows, and technology, along with ongoing compliance monitoring.

OpenLoop’s virtual care infrastructure is built to support healthcare organizations launching and scaling peptide programs, whether you are expanding an existing offering or exploring peptide treatments for the first time. 

Learn more about how to offer a peptide therapy program for your business. 

Compounded drugs are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality. The peptides discussed in this article have not been approved by FDA for recovery or performance. Compounded preparations require a prescription following an appropriate clinical evaluation, and no prescription is guaranteed. Availability varies based on clinical appropriateness, applicable federal and state laws, pharmacy availability, and other regulatory requirements. Not all peptide therapies are available in all states or through all pharmacies.

This content is for general informational purposes only. It is not medical or legal advice and does not create a clinician-patient or attorney-client relationship. For guidance on your specific situation, consult a licensed clinician or attorney.

References

Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db [mice]. 

Google Ads Keyword Planner. Search volume for the keyword “peptide,” June 2025–July 2026. Internal export on file with OpenLoop Marketing.

U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability). Federal Register Doc. 2026-22192, published October 30, 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances

McDermott Will & Schulte. Peptides first, paperwork later: HHS clears six for compounding ahead of bulks list rulemaking. https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/

U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Appendix B (substance identity and permitted routes of administration). https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

U.S. Food and Drug Administration. Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026 (introduction and substance-specific briefing documents). https://www.fda.gov/media/193342/download

U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee (announcement of a meeting before the end of February 2027). https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee

Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325.

U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy text). https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf

U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (describes the statutory conditions and the interim policy categories). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act

BakerHostetler (via Lexology). HHS Issues Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. https://www.lexology.com/library/detail.aspx?g=60e6b7a9-bf1f-4e8d-be3e-959707709e4d

World Anti-Doping Agency. Prohibited List https://www.wada-ama.org/en/prohibited-list

Drug Topics. FDA panel to evaluate 7 popular peptides for compounding substances list (summary of FDA briefing documents). https://www.drugtopics.com/view/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list

Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PMID 18031173. https://pubmed.ncbi.nlm.nih.gov/18031173/

U.S. Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. 78 Fed. Reg. 14095 (March 4, 2013).

Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. 2025. PMID 40756949. https://pubmed.ncbi.nlm.nih.gov/40756949/

U.S. Food and Drug Administration. Briefing Document: BPC-157-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23, 2026. https://www.fda.gov/media/193343/download

Regulatory Affairs Professionals Society. FDA advisory committee backs two controversial peptides (July 23, 2026). https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html

Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID 25738459. https://pubmed.ncbi.nlm.nih.gov/25738459/

Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PMID 16996037. https://pubmed.ncbi.nlm.nih.gov/16996037/

U.S. Food and Drug Administration. Briefing Document: Semax-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 24, 2026. https://www.fda.gov/media/193348/download

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID 18061177. https://pubmed.ncbi.nlm.nih.gov/18061177/

U.S. Food and Drug Administration. Briefing Document: KPV-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23, 2026. https://www.fda.gov/media/193346/download

U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (list updated May 14, 2026). https://www.fda.gov/media/94155/download

Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID 15565145. https://pubmed.ncbi.nlm.nih.gov/15565145/

Shrivastava S, Srivastava D, Olson EN, DiMaio JM, Bock-Marquette I. Thymosin β4 and cardiac repair. Ann N Y Acad Sci. 2010;1194:87-96.

Cardioprotection by Thymosin Beta 4 (review chapter). 2016. https://www.sciencedirect.com/science/chapter/bookseries/abs/pii/S0083672916300048 

Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta 4: a novel corneal wound healing and anti-inflammatory agent. Clin Ophthalmol. 2007. PMID 19668473. https://pubmed.ncbi.nlm.nih.gov/19668473/

Sosne G, Chan CC, Thai K, et al. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res. 2001;72:605-608.

Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74:293-299.

Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PMID 10469335. https://pubmed.ncbi.nlm.nih.gov/10469335/

Ready to take your brand
to the next level?

Contact us today 
OpenLoop banner ad. Text reads "You focus on your business. We power the care. The short virtual care launch." with a "See how it works" button. A Monday-to-Friday timeline shows a branded site in as little as 24 hours on Monday and program launch on Friday. Fine print notes the timeline is an estimate and actual launch dates may vary by practice.

Explore more related topics